MK-677 Dosage: What the Research Reports

What is MK-677 and how does it work?

MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that signals the pituitary gland to release more growth hormone, which then raises IGF-1 (Nass et al., 2008).

Because it mimics ghrelin, MK-677 is grouped with the growth hormone secretagogues, a class of compounds that prompt the body's own growth hormone release rather than adding growth hormone directly. What sets MK-677 apart from most of the class is the route: it is active by mouth, so the trial protocol used a single daily oral dose (Nass et al., 2008). Injectable secretagogues work through related but different pathways. CJC-1295 is a growth hormone releasing hormone analog that raised mean growth hormone about 2 to 10 fold and IGF-1 about 1.5 to 3 fold in healthy adults (Teichman et al., JCEM 2006), and ipamorelin is a selective growth hormone secretagogue with minimal effect on cortisol and prolactin (Raun et al., Eur J Endocrinol 1998).

What MK-677 dosage does published research report?

The most-cited human study administered 25 mg of MK-677 orally once daily in healthy older adults, with the primary analysis reported at 12 months (Nass et al., 2008).

That trial randomized 65 healthy older adults, about 60 to 81 years of age, to either MK-677 or placebo. The table below summarizes what the study reported at that single 25 mg per day oral dose. Every figure here is what researchers measured in that trial, not a suggestion for personal use.

This is the anchor number people mean when they ask about "MK-677 dosage": 25 mg, taken orally, once per day, in a research setting. It is one dose from one trial, not a personalized instruction.

What did the 25 mg dose do to glucose and insulin?

At 25 mg per day, participants showed higher fasting blood glucose, about 0.3 mmol/L (5 mg/dL), and reduced insulin sensitivity over the trial (Nass et al., 2008).

This is the finding that matters most when people copy a research dose without a clinician. Higher growth hormone can blunt insulin's effect, and in this trial the same protocol that raised IGF-1 and fat-free mass also raised fasting glucose and lowered insulin sensitivity (Nass et al., 2008). The trial reported these as measurable changes over daily use. That combination, more IGF-1 but weaker glucose control, is why the metabolic side of MK-677 belongs in a conversation with a qualified clinician, especially for anyone who already tracks blood sugar.

How does MK-677 dosing compare with injectable secretagogues?

MK-677 is taken by mouth once daily, while peptides like CJC-1295 and ipamorelin were studied as injectables on different schedules (Teichman et al., 2006; Raun et al., 1998).

The dosing conversation for MK-677 is different from the injectable secretagogues mostly because of route and how the compound is measured. MK-677 is dosed in milligrams by mouth. The injectable peptides are dosed differently and delivered under the skin. The grid below compares the class at a high level, with a source for each row. It does not list injectable doses, because a research dose for one compound is not transferable to another.

Is MK-677 approved, and what side effects did research report?

MK-677 is not approved as a medicine, and the clearest signals from the trial were higher fasting glucose, lower insulin sensitivity, and increased appetite (Nass et al., 2008).

MK-677 is sold and handled as a research compound, not a prescription product. In the trial, the glucose and insulin changes appeared over daily use, and appetite rose in a way that fits its action as a ghrelin mimetic, though that appetite increase subsided within a few months (Nass et al., 2008). The study also noted transient, mild lower-limb swelling and muscle pain (Nass et al., 2008). None of this is a medical claim about what MK-677 does for a person outside a study; it is a summary of what one controlled trial measured. Human data on MK-677 remains limited to a small number of studies, so long-term effects at any dose are not fully characterized.

Why should personal MK-677 dosing go through a clinician?

Because the studied dose raised blood glucose and lowered insulin sensitivity, and because MK-677 is not an approved medicine, any decision about personal use belongs with a qualified clinician (Nass et al., 2008).

The 25 mg figure is easy to find and easy to copy, but a research protocol in monitored healthy adults is not a plan for an individual. A clinician can weigh personal factors that a trial average cannot, including blood sugar, existing conditions, and other compounds. This page reports what the research measured so you can ask better questions, not so you can dose yourself.